Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo pill could ease opioid withdrawal for outpatients

NCT ID NCT05995535

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding pregabalin to the standard withdrawal drug lofexidine helps people with opioid use disorder feel less sick while quitting. About 150 adults who want to start long-acting naltrexone will take either the combination or a placebo for 8 days. The goal is to see if the combo reduces withdrawal symptoms and helps more people complete detox and start recovery treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male and/or female subjects ≥ 18 years of age 2. Meet DSM-5 criteria for an Opioid Use Disorder with physiologic features. Have met 2 or more of the 11 criteria for an OUD including tolerance and withdrawal within the last 12 months 3. Interested in opioid antagonist treatment 4. Used opioids in 20 or more of the last 30 days 5. A stable address in the local area; not planning to move in the next 60 days. 6. Have documents for ID check 7. Absence of medical or psychiatric conditions that are likely to interfere with study participation 8. Has 12 lead ECG demonstrating a QTc ≤450 msec and a QRS ≤120 msec. Site PI has final determination for study inclusion if readings exceed these limits. The PENN cardiologists and medical monitor are available for consultation when needed 9. Negative pregnancy test and using adequate contraception if of childbearing potential. Exclusion Criteria: 1. Current psychotic disorder (bipolar I, schizophrenia, major depression that is not in remission 2. Alcohol, benzodiazepine, or other sedative use disorder with physiological features that require medication for detoxification 3. Allergy or other serious adverse event due to treatment with pregabalin, XR-NTX, or lofexidine 4. Pending incarceration or plans to leave the immediate area in the next 30 days 5. Homicidal or otherwise behaviorally disturbed requiring immediate attention 6. High risk for suicide as determined by answering 'yes' to questions 4 and/or 5 on C-SSRS 7. Blood pressure \<90 mm Hg (systolic) or \<60 mm Hg (diastolic). If value out of normal range, the investigator and study Clinician will decide subject inclusion/exclusion on case-by-case basis 8. Heart rate and/or pulse\<50 bpm at screening-sitting 9. An Estimated Glomerular Filtration Rate eGFR\<70 mL/min/1.73m2 10. A History of, or current Seizure disorder (excluding childhood febrile seizures) 11. Inability to read and/or understand English. For example, unable to understand the informed consent as demonstrated by failing to answer 9/10 questions correctly on the quiz 12. 12\. Pregnant or breastfeeding 13. 13\. Currently taking sympathomimetic drugs, or a thiazolidinedione antidiabetic 14. ALT and/or AST \>4X upper limit of normal 15. A Child-Pugh score \>7 16. Currently receiving opioids for pain management 17. In a treatment study where medication was administered in the last 30 days 18. Currently using medications that are known to be strong or moderate inhibitors of CYP2D6 such as fluoxetine, paroxetine, mirabegron, bupropion, quinidine, terbinafine, cimetidine, cinacalcet, duloxetine, or fluvoxamine 19. In a methadone maintenance or buprenorphine treatment program within the last 30 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opiate withdrawal syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mountain Manor Treatment Center

    NOT_YET_RECRUITING

    Baltimore, Maryland, 21229-3618, United States

  • University of Pennsylvania, Treatment Research Center

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.